09:28 AM EDT, 06/10/2026 (MT Newswires) -- Hercules Capital ( HTGC ) is providing up to $165 million in non-dilutive financing to Beren Therapeutics as part of a $300 million funding package aimed at supporting the potential launch of adrabetadex, Beren Therapeutics said Wednesday.

The financing includes up to $110 million in milestone-based senior-secured term loans and a $55 million royalty agreement contingent on FDA approval.

Beren said the funds will support launch preparations ahead of its Nov. 17 PDUFA date for adrabetadex in infantile-onset Niemann-Pick disease type C, along with patient access and long-term support initiatives.